UCB Archives -

Considerable scientific progress across neurological diseases and disorders was reported at the recent 74th American Academy of Neurology

Recent advances in neurological disorders

https://pharmaphorum.com/r-d/recent-advances-in-neurological-disorders/

Market Access/ News/ News

FDA rejects UCB’s psoriasis therapy bimekizumab

Phil Taylor bimekizumab, fda, psoriasis, regulatory, UCB 0 Comment

The FDA has delivered a blow to UCB’s late-stage pipeline, after saying it is unable to approve its

FDA rejects UCB’s psoriasis therapy bimekizumab

https://pharmaphorum.com/news/fda-rejects-ucbs-psoriasis-therapy-bimekizumab/

Patients/ Views & Analysis/ Views and analysis

Engagement to partnership: The changing face of patient involvement

Amanda Barrell Iris Loew-Friedrich, patient engagement, UCB 0 Comment

The era of patient engagement is over. Instead, it’s time to move towards true partnership at every step

Engagement to partnership: The changing face of patient involvement

https://pharmaphorum.com/patients/engagement-to-partnership-changing-face-patient-involvement/

Market Access/ News/ News

NICE ends UK access disparity to osteoporosis drug Evenity

Phil Taylor Amgen, Evenity, HEOR, NHS, osteoporosis, UCB 0 Comment

NICE has reversed its stance on UCB and Amgen’s severe osteoporosis therapy Evenity, saying out can be prescribed

NICE ends UK access disparity to osteoporosis drug Evenity

https://pharmaphorum.com/news/nice-ends-uk-access-disparity-to-osteoporosis-drug-evenity/

News/ News/ R&D

UCB preps filings for another challenger to AZ’s Soliris

Phil Taylor Apellis Pharma, Argenx, AstraZeneca, myasthenia gravis, rozanolixizumab, Soliris, UCB, Ultomiris, zilucoplan 0 Comment

Belgian drugmaker UCB says it will be able to file not one but two new drug therapies for

UCB preps filings for another challenger to AZ’s Soliris

https://pharmaphorum.com/news/ucb-preps-filings-for-another-challenger-to-azs-soliris/

News/ News/ R&D

UCB chases after Argenx with FcRN drug for myasthenia gravis

Phil Taylor Argenx, autoimmune disease, efgartigimod, myasthenia gravis, rozanolixizumab, UCB 0 Comment

UCB has the positive result it was hoping for in its phase 3 trial of anti-neonatal FC receptor

UCB chases after Argenx with FcRN drug for myasthenia gravis

https://pharmaphorum.com/news/ucb-chases-after-argenx-with-fcrn-drug-for-myasthenia-gravis/

Close Up Of Senior Man Suffering With Parkinsons Diesease

News/ News/ R&D

Novartis takes aim at risky Parkinson’s target with $1.5bn UCB deal

Phil Taylor neurology, Novartis, Parkinson's disease, partnering, UCB 0 Comment

Novartis has licensed a potential drug for Parkinson’s from Belgium’s UCB that it thinks could be the first

Novartis takes aim at risky Parkinson’s target with $1.5bn UCB deal

https://pharmaphorum.com/news/novartis-takes-aim-at-risky-parkinsons-target-with-1-5bn-ucb-deal/

Digital/ News/ News

Pharma group will develop ‘digital endpoint’ for atopic dermatitis

Phil Taylor AbbVie, atopic dermatitis, clinical trials, digital, digital endpoint, digital health, Janssen, Novartis, Pfizer, UCB 0 Comment

The development of digital medicine requires valid endpoints that can be used in clinical trials, and a consortium

Pharma group will develop ‘digital endpoint’ for atopic dermatitis

https://pharmaphorum.com/news/pharma-group-will-develop-digital-endpoint-for-atopic-dermatitis/

Digital/ News/ News

UCB licenses AI tech for spinal fracture detection to ImageBiopsy

Phil Taylor bone, diagnostic, digital, digital health, ImageBiopsy Lab, osteoporosis, UCB 0 Comment

An artificial intelligence-based tool for identifying hard-to-detect spinal fractures, developed by Belgian drugmaker UCB, has been licensed out

UCB licenses AI tech for spinal fracture detection to ImageBiopsy

https://pharmaphorum.com/news/ucb-licenses-ai-tech-for-spinal-fracture-detection-to-imagebiopsy/

Trending

UCB

Login